Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Puerto Rico Healthcare Daily.
Press releases published on July 9, 2025
Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures Announce Generative-AI Driven Lead Discovery Collaboration
GlobeNewswire
·
July 9, 2025
Joint research program targets new treatments for life-threatening complication of brain hemorrhage An international discovery collaboration is harnessing AI-powered drug discovery to develop a first-in-class therapy to prevent delayed cerebral ischemia in …
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
GlobeNewswire
·
July 9, 2025
Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts trial profile Enrollment in Part A of MIRACLE reaches …
Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines
GlobeNewswire
·
July 9, 2025
Grand Cayman, Cayman Islands, July 09, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today …
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
GlobeNewswire
·
July 9, 2025
GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related …
TRIMEDX ranked 30th Inspiring Workplace in North America and recognized as Best in Class Leadership
GlobeNewswire
·
July 9, 2025
Indianapolis, Indiana, July 09, 2025 (GLOBE NEWSWIRE) -- TRIMEDX―a leading independent clinical asset management company delivering clinical engineering services, clinical asset informatics, and medical device cybersecurity― is proud to announce it has …
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
GlobeNewswire
·
July 9, 2025
LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) to evaluate …
Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements
GlobeNewswire
·
July 9, 2025
NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today …
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
GlobeNewswire
·
July 9, 2025
Fountain Life operates four flagship longevity centers, including two in Florida, where a new state law effective July 1, 2025, authorizes licensed physicians to administer stem cell therapies to members with conditions in orthopedics, wound care, and pain …
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire
·
July 9, 2025
CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has regained compliance with Nasdaq for …
Clover Health Launches New Jersey Community Pharmacy Program in Partnership with IPC’s iCare+ Network
GlobeNewswire
·
July 9, 2025
WILMINGTON, Del., July 09, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a leading Medicare Advantage company committed to affordable, high-quality care, today announced the launch of a new community-based …
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies
GlobeNewswire
·
July 9, 2025
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Therapeutics HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- …
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
GlobeNewswire
·
July 9, 2025
HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
Vireo Growth Inc. Announces Retirement of November 2024 Convertible Note
GlobeNewswire
·
July 9, 2025
-- Company concurrently refinances convertible note on amended terms in conjunction with larger refinancing -- MINNEAPOLIS, July 09, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF) today announced the …
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036
GlobeNewswire
·
July 9, 2025
SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today …
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire
·
July 9, 2025
ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell …
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
GlobeNewswire
·
July 9, 2025
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response with LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a …
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
GlobeNewswire
·
July 9, 2025
NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
GlobeNewswire
·
July 9, 2025
Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidates Iambic to receive up to $25 million through a combination of upfront and expected near-term performance-based milestone payments for services …
Dr. Anosh Ahmed Plans $25,000 Donation to Support FBI Families and Law Enforcement Mental Health Programs
GlobeNewswire
·
July 9, 2025
Image by Dr. Anosh Ahmed CHICAGO, July 09, 2025 (GLOBE NEWSWIRE) -- Dr. Anosh Ahmed, a Chicago-based physician and founder of the Anosh Inc Foundation, has announced plans to donate $25,000 to nonprofit organizations that support FBI agents and their …
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
GlobeNewswire
·
July 9, 2025
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 09, 2025 ( …